Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 4/20 | 0.50 |
| ▸ | RXRA | P19793 | 6/20 | 0.48 |
| ▸ | GRIN1 | Q05586 | 6/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.48 |
| ▸ | MAOA | P21397 | 6/20 | 0.46 |
| ▸ | MAOB | P27338 | 4/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5622168 | 0.88 | NOTUM (0.53) | NOTUMRXRAGRIN1GRIN2B | |
| SCHEMBL5623484 | 0.85 | NOTUM (0.50) | NOTUMRXRAGRIN1GRIN2BMAOA | |
| SCHEMBL5623083 | 0.85 | NOTUM (0.45) | NOTUMRXRAGRIN1GRIN2BMAOA | |
| SCHEMBL5622583 | 0.85 | NOTUM (0.51) | NOTUMRXRAGRIN1GRIN2BMAOA | |
| SCHEMBL14527037 | 0.83 | NOTUM (0.48) | NOTUMRXRAGRIN1GRIN2BMAOA | |
| SCHEMBL14527033 | 0.83 | NOTUM (0.48) | NOTUMRXRAGRIN1GRIN2BMAOA | |
| SCHEMBL14527035 | 0.83 | NOTUM (0.48) | NOTUMRXRAGRIN1GRIN2BMAOA | |
| SCHEMBL5624771 | 0.82 | MAOB (0.46) | NOTUMRXRAGRIN1GRIN2BMAOA | |
| SCHEMBL14527061 | 0.82 | MAOB (0.46) | NOTUMRXRAGRIN1GRIN2BMAOA | |
| SCHEMBL5623184 | 0.82 | RXRA (0.43) | RXRAGRIN1GRIN2BMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202254-B2 | Antibacterial compounds: process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LIMITED (IN) | 2007-04-10 | — | — | US | disclosed |
| US-7202254-B2 | Antibacterial compounds: process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LIMITED (IN) | 2007-04-10 | — | — | US | disclosed |
| US-7202254-B2 | Antibacterial compounds: process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LIMITED (IN) | 2007-04-10 | — | — | US | disclosed |
| US-20050209223-A1 | Novel antibacterial compounds: process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LIMITED | 2005-09-22 | — | — | US | disclosed |
| US-6914058-B2 | 1-(p-(thiomorpholino)phenyl)-1,2,3-triazole derivatives | DR. REDDY'S LABORATORIES, LIMITED (IN) | 2005-07-05 | — | — | US | disclosed |
| US-20050113347-A1 | NOVEL ANTIBACTERIAL COMPOUNDS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S LABORATORIES LIMITED | 2005-05-26 | — | — | US | disclosed |
| EP-1467977-A1 | NOVEL ANTIBACTERIAL COMPOUNDS:PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | Dr. Reddy's Laboratories Ltd. (IN) | 2004-10-20 | — | — | EP | disclosed |
| WO-2003059894-A1 | NOVEL ANTIBACTERIAL COMPOUNDS:PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | DR.REDDY'S LABORATORIES LTD. (IN) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209223-A1 | Novel antibacterial compounds: process for their preparation and pharmaceutical compositions containing them | CYP3A4, CYP3A43, CYP3A5 | NOTUM 4524/4885RXRA 2590/4885GRIN1 3906/4885 |
| US-20050113347-A1 | NOVEL ANTIBACTERIAL COMPOUNDS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CYP3A4, CYP3A43, CYP3A5 | NOTUM 4524/4885RXRA 2590/4885GRIN1 3906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.